Statin Therapy After Myocardial Infarction in Patients With Renal Failure: The Longer, the Merrier!

J Cardiovasc Pharmacol. 2023 Jun 1;81(6):392-394. doi: 10.1097/FJC.0000000000001420.

Authors

Luigi Spadafora^{1

2}, Gabriele Crimi², Italo Porto², Giuseppe Biondi-Zoccai^{3

4}

Affiliations

¹ Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
² Cardiology Unit, Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
³ Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; and.
⁴ Mediterranea Cardiocentro, Naples, Italy.

PMID: 36930569
DOI: 10.1097/FJC.0000000000001420

No abstract available

Publication types

Comment

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Myocardial Infarction* / chemically induced
Myocardial Infarction* / drug therapy
Renal Insufficiency* / diagnosis
Treatment Outcome

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors